3353 Medical Ikkou Group Co.,Ltd. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

3353

TSE Standard

Medical Ikkou Group Co.,Ltd.

2,684

JPY

-11

(-0.41%)

Dec 5, 3:30 pm JST

17.36

USD

Dec 5, 1:30 am EST

Result

PTS

outside of trading hours

ー

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Feb, 2022	33,595	1,275	1,357	852	226.9	40	Apr 8, 2022	J-GAAP
Feb, 2023	33,897	935	1,227	759	202.2	40	Apr 7, 2023	J-GAAP
Feb, 2024	39,900	1,559	1,751	1,039	276.7	45	Apr 5, 2024	J-GAAP
Feb, 2025	48,393	1,692	1,816	1,133	301.4	65	Apr 4, 2025	J-GAAP
Feb, 2026 Guidance	53,000	1,600	1,800	1,250	331.9	120	Oct 23, 2025	J-GAAP
YoY	+9.5%	-5.4%	-0.9%	+10.3%	+10.1%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Feb, 2021	Apr 10, 2020	32,430	1,240	1,250	805	40	J-GAAP
Results	Apr 12, 2021	31,603	1,028	1,201	834	40	J-GAAP
Feb, 2022	Apr 12, 2021	Available in future release
Results	Apr 8, 2022
Feb, 2023	Apr 8, 2022
	Jan 10, 2023
Results	Apr 7, 2023
Feb, 2024	Apr 7, 2023
	Jul 31, 2023
	Feb 21, 2024
Results	Apr 5, 2024
Feb, 2025	Apr 5, 2024
	Mar 28, 2025
Results	Apr 4, 2025
Feb, 2026	Apr 4, 2025	52,500	1,950	1,900	1,250	120	J-GAAP
	Oct 23, 2025	53,000	1,600	1,800	1,250	120	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Feb, 2001	5,099	+24.9	Available in future release
Feb, 2002	6,005	+17.8
Feb, 2003	6,524	+8.6
Feb, 2004	7,709	+18.2
Feb, 2005	9,270	+20.2
Feb, 2006	10,557	+13.9
Feb, 2007	12,362	+17.1
Feb, 2008	14,662	+18.6
Feb, 2009	16,068	+9.6
Feb, 2010	17,184	+6.9
Feb, 2011	17,974	+4.6
Feb, 2012	19,576	+8.9
Feb, 2013	20,574	+5.1
Feb, 2014	22,873	+11.2
Feb, 2015	26,387	+15.4
Feb, 2016	29,305	+11.1
Feb, 2017	29,489	+0.6
Feb, 2018	30,914	+4.8
Feb, 2019	31,222	+1.0
Feb, 2020	32,042	+2.6
Feb, 2021	31,603	-1.4
Feb, 2022	33,595	+6.3
Feb, 2023	33,897	+0.9
Feb, 2024	39,900	+17.7
Feb, 2025	48,393	+21.3
Feb, 2026 Guidance	53,000	+9.5	1,600	-5.4	1,800	-0.9	331.9	+10.1

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Feb, 2024	39,900	1,559	3.91	8.22	3.51	1.35	276.7
Feb, 2025	48,393	1,692	3.50	8.29	3.44	1.47	301.4
Feb, 2026 Guidance	53,000	1,600	3.02	8.54	3.30	1.40	331.9

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	48,393	1,692	1,816	1,238	323.1
Fiscal Year	Feb, 2025	Feb, 2025	Feb, 2025	Feb, 2018	Feb, 2018

Second Half

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Sep - Feb, 2022	16,919	470	629	385	102.6	20	Apr 7, 2023	J-GAAP
Sep - Feb, 2023	22,450	956	1,055	595	158.5	25	Apr 5, 2024	J-GAAP
Sep - Feb, 2024	25,728	864	963	424	112.8	40	Apr 4, 2025	J-GAAP
Sep - Feb, 2025 Guidance	26,065	857	920	584	155.1	60	Oct 23, 2025	J-GAAP
YoY	+1.3%	-0.8%	-4.5%	+37.7%	+37.5%

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Feb, 2023	935	830	1,307	-477	-2,366	6,253	22.73	J-GAAP
Feb, 2024	1,559	1,059	4,277	-3,218	277	7,589	23.97	J-GAAP
Feb, 2025	1,692	64	1,198	-1,134	-1,027	6,639	19.39	J-GAAP

Actual Performance and Financial Trends

Accumulated Results 2nd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Mar - Aug, 2023	17,450	603	696	444	118.3	39.7	Oct 2, 2023	J-GAAP
Mar - Aug, 2024	22,665	828	853	709	188.8	47.0	Oct 7, 2024	J-GAAP
Mar - Aug, 2025	26,935	743	880	666	177.2	46.3	Oct 6, 2025	J-GAAP
YoY	+18.8%	-10.3%	+3.2%	-6.1%	-6.1%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Sep - Nov, 2023	11,319	475	494	368	98.0	4.2	Jan 10, 2024	J-GAAP
Dec - Feb, 2023	11,131	481	561	227	60.5	4.3	Apr 5, 2024	J-GAAP
Mar - May, 2024	11,183	429	430	429	114.2	3.8	Jul 8, 2024	J-GAAP
Jun - Aug, 2024	11,482	399	423	280	74.5	3.5	Oct 7, 2024	J-GAAP
Sep - Nov, 2024	12,425	375	423	290	77.2	3.0	Jan 10, 2025	J-GAAP
Dec - Feb, 2024	13,303	489	540	134	35.6	3.7	Apr 4, 2025	J-GAAP
Mar - May, 2025	13,423	434	491	438	116.5	3.2	Jul 7, 2025	J-GAAP
Jun - Aug, 2025	13,512	309	389	228	60.7	2.3	Oct 6, 2025	J-GAAP
YoY	+17.7%	-22.6%	-8.0%	-18.6%	-18.6%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Sep - Nov, 2020	7,962	-0.2	Available in future release
Dec - Feb, 2020	8,119	+1.5
Mar - May, 2021	8,505	+8.7
Jun - Aug, 2021	8,307	+7.9
Sep - Nov, 2021	8,399	+5.5
Dec - Feb, 2021	8,384	+3.3
Mar - May, 2022	8,563	+0.7
Jun - Aug, 2022	8,415	+1.3
Sep - Nov, 2022	8,449	+0.6
Dec - Feb, 2022	8,470	+1.0
Mar - May, 2023	8,721	+1.8
Jun - Aug, 2023	8,729	+3.7
Sep - Nov, 2023	11,319	+34.0
Dec - Feb, 2023	11,131	+31.4
Mar - May, 2024	11,183	+28.2
Jun - Aug, 2024	11,482	+31.5
Sep - Nov, 2024	12,425	+9.8
Dec - Feb, 2024	13,303	+19.5
Mar - May, 2025	13,423	+20.0
Jun - Aug, 2025	13,512	+17.7	309	-22.6	389	-8.0	60.7	-18.5

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	13,512	489	561	526	137.3
Fiscal Year	Aug, 2025	Feb, 2024	Feb, 2023	Aug, 2017	Aug, 2017

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Feb, 2023	3,207.14	43.8	27,505	12,049	10,557	0.76	Apr 7, 2023	J-GAAP
Feb, 2024	3,523.25	41.8	31,659	13,240	11,447	0.72	Apr 5, 2024	J-GAAP
Feb, 2025	3,747.70	41.2	34,231	14,097	12,391	0.71	Apr 4, 2025	J-GAAP
Mar - Aug, 2025	ー	38.6	37,914	14,636	12,414	0.78	Oct 6, 2025	J-GAAP

Medical Ikkou Group Co.,Ltd.(3353) Financial Results